Literature DB >> 18277885

Defining surgical therapy for pseudomembranous colitis with toxic megacolon.

Loren Berman1, Tobias Carling, Tamara N Fitzgerald, Robert L Bell, Andrew J Duffy, Walter E Longo, Kurt E Roberts.   

Abstract

BACKGROUND: Pseudomembranous colitis has increased in incidence and severity over the past 10 years. Toxic megacolon is a rare but reported presentation of severe pseudomembranous colitis. This article reviews the reported cases of Clostridium difficile with toxic megacolon in the literature and introduces an additional case that underscores the importance of early diagnosis in guiding appropriate therapy.
METHODS: A systematic review of the literature was performed to identify previous reports of pseudomembranous colitis presenting with toxic megacolon, and the outcomes of each of these cases was analyzed. The review was focused on atypical presentations in immunocompromised patients.
RESULTS: Seventeen cases of C. difficile colitis presenting as toxic megacolon were identified. The overall mortality rate was 50% (9/18). Fifteen patients underwent surgery with an associated mortality rate of 50%. Thirteen patients had a subtotal colectomy. Seven of the patients (39%) were taking immunosuppressant medications, and 5 (28%) patients presented with atypical symptoms. Three (76%) of those were immunosuppressed. In several cases, failure to make an early diagnosis of C. difficile colitis resulted in a worse outcome because appropriate therapy was delayed.
CONCLUSIONS: Toxic megacolon is well-established as an unusual presentation of C. difficile colitis. These patients are less likely to present with typical symptoms such as diarrhea or typical risk factors like recent administration of antibiotics, so diagnosis can be a challenge. A patient presenting with toxic megacolon without a history of inflammatory bowel disease should be assumed to have C. difficile colitis until proven otherwise, and medical or surgical therapy administered accordingly.

Entities:  

Mesh:

Year:  2008        PMID: 18277885     DOI: 10.1097/MCG.0b013e31804bbe12

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

Review 1.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

2.  Fecal Microbiota Transplant for Clostridium difficile Colitis-Induced Toxic Megacolon.

Authors:  S P Costello; A Chung; J M Andrews; R J Fraser
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

Review 3.  Laboratory diagnosis of bacterial gastroenteritis.

Authors:  Romney M Humphries; Andrea J Linscott
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

4.  Rapid evolution of the human gut virome.

Authors:  Samuel Minot; Alexandra Bryson; Christel Chehoud; Gary D Wu; James D Lewis; Frederic D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

5.  Toxic megacolon associated Clostridium difficile colitis.

Authors:  Leena Sayedy; Darshan Kothari; Robert J Richards
Journal:  World J Gastrointest Endosc       Date:  2010-08-16

Review 6.  Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation.

Authors:  Yvette H van Beurden; Max Nieuwdorp; Pablo J E J van de Berg; Chris J J Mulder; Abraham Goorhuis
Journal:  Therap Adv Gastroenterol       Date:  2017-02-08       Impact factor: 4.409

7.  Cec and You Shall Find: Cecal Perforation in a Patient with COVID-19.

Authors:  Ioana Baiu; Erna Forgó; Cindy Kin; Thomas G Weiser
Journal:  Dig Dis Sci       Date:  2021-01-25       Impact factor: 3.199

8.  The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series.

Authors:  Christine M Akamine; Michael B Ing; Christian S Jackson; Lawrence K Loo
Journal:  BMC Infect Dis       Date:  2016-07-07       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.